Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.60 |
| ▸ | TDP2 | O95551 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.50 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4407221 | 0.89 | TDP2 (0.59) | PKMTDP2TDP1MAPTPIP4K2A | |
| SCHEMBL6525259 | 0.84 | PKM (0.56) | PKMTDP1MAPTIDO1AHR | |
| SCHEMBL29554536 | 0.81 | PKM (0.53) | PKMTDP1MAPTIDO1AHR | |
| SCHEMBL5636293 | 0.80 | PKM (0.73) | PKMTDP1MAPTBRD4 | |
| SCHEMBL12361998 | 0.80 | AHR (0.56) | PKMTDP1MAPTIDO1AHR | |
| SCHEMBL5167999 | 0.80 | PKM (0.65) | PKMTDP1MAPTIDO1BRD4 | |
| SCHEMBL3038643 | 0.77 | TDP1 (0.65) | PKMTDP1MAPTIDO1AHR | |
| SCHEMBL31681272 | 0.76 | PKM (0.65) | PKMTDP1MAPTIDO1BRD4 | |
| SCHEMBL23066125 | 0.76 | AHR (0.51) | PKMTDP1MAPTIDO1AHR | |
| SCHEMBL13993996 | 0.76 | KIF11 (0.53) | PKMTDP1MAPTIDO1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350458-A1 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | RAPPOSELLI SIMONA (IT) | 2024-10-24 | — | — | US | disclosed |
| EP-3204002-B1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS | INTERNATIONAL SOC FOR DRUG DEVELOPMENT S R L (IT) | 2021-05-19 | — | — | EP | disclosed |
| EP-3204002-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS | International Society for Drug Development S.r.l. (IT) | 2017-08-16 | — | — | EP | disclosed |
| EP-2581371-B1 | PYRROLYL SUBSTITUTED DIHYDROINDOL-2-ONE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | QILU PHARMACEUTICAL CO LTD (CN) | 2017-06-07 | — | — | EP | disclosed |
| WO-2016055454-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS | INTERNATIONAL SOCIETY FOR DRUG DEVELOPMENT S.R.L. (IT) | 2016-04-14 | — | — | WO | disclosed |
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-8697692-B2 | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2014-04-15 | — | — | US | disclosed |
| US-8637681-B2 | Pyrrolyl substituted dihydroindol-2-one derivatives, preparation methods and uses thereof | QILU PHARMACEUTICAL CO., LTD. (CN) | 2014-01-28 | — | — | US | disclosed |
| EP-1973910-B1 | PYRROLO[3,2-C]PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2013-06-26 | — | — | EP | disclosed |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-01-07 | — | — | US | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
| EP-1973910-A1 | PYRROLO Ý3,2-C¨PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007085188-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2007-08-02 | — | — | WO | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | PKM 477/4885TDP2 1093/4885TDP1 1082/4885 |
| US-20100004239-A1 | Pyrrolo [3,2-C] Pyridine-4-One 2-Indolinone Protein Kinase Inhibitors | DMPK, CDK2, PRKAR2A | PKM 313/4885TDP2 1581/4885TDP1 1553/4885 |
| US-20240350458-A1 | 14-3-3 PROTEIN MODULATORS AS ANTITUMOR AGENTS | YWHAH, YWHAB, YWHAG | PKM 4682/4885TDP2 2720/4885TDP1 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.